# Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

> **NCT02289144** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Metastatic Anaplastic Thyroid Cancer
- Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer

## Interventions

- **DRUG:** Ceritinib

## Key facts

- **NCT ID:** NCT02289144
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study was on hold for protocol redesign; decided to not move forward with study.
- **Last updated:** 2019-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289144, "Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02289144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*